• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • NME Digest
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Under threat: mRNA vaccine research
  • BioWorld at 35
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » WRN inhibitors

Articles Tagged with ''WRN inhibitors''

Cancer

Forx Therapeutics describes new WRN inhibitors

Oct. 1, 2025
Forx Therapeutics AG has identified Werner syndrome ATP-dependent helicase (WRN; RECQ3; RECQL2) inhibitors reported to be useful for the treatment of cancer.
Read More
Cancer

Nanjing Zaiming Pharmaceutical divulges new WRN inhibitors

Sep. 18, 2025
Nanjing Zaiming Pharmaceutical Co. Ltd. has synthesized Werner syndrome ATP-dependent helicase (WRN; RECQ3; RECQL2) inhibitors reported to be useful for the treatment of cancer.
Read More
AI-generated image for cancer cells observed under a microscope
Cancer

Moma’s WRN inhibitor causes preclinical tumor regression

Aug. 29, 2025
No Comments
Moma Therapeutics Inc. has released data regarding their Werner syndrome helicase (WRN) inhibitor MOMA-341 for the potential treatment of cancer. MOMA-341 is a potent and selective WRN inhibitor, the action of which is through covalent ligation.
Read More
Cancer

Foresight Therapeutics discovers new WRN inhibitors

Aug. 27, 2025
Foresight Therapeutics (Hefei) Co. Ltd. has described Werner syndrome ATP-dependent helicase (WRN; RECQ3; RECQL2) inhibitors reported to be useful for the treatment of cancer.
Read More
Cancer

New WRN inhibitors disclosed in Inventisbio patent

Aug. 22, 2025
Inventisbio Co. Ltd. and Inventisbio LLC have divulged Werner syndrome helicase (WRN; RECQ3; RECQL2) inhibitors reported to be useful for the treatment of cancer.
Read More
Cancer

Shanghai Qilu Pharmaceutical divulges new WRN inhibitors

Aug. 14, 2025
Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. has synthesized Werner syndrome ATP-dependent helicase (WRN; RECQ3; RECQL2) inhibitors reported to be useful for the treatment of cancer.
Read More
Cancer

New WRN inhibitors disclosed in Chengdu Chipscreen Pharmaceutical patent

Aug. 11, 2025
Chengdu Chipscreen Pharmaceutical Ltd. has divulged Werner syndrome ATP-dependent helicase (WRN; RECQ3; RECQL2) inhibitors reported to be useful for the treatment of cancer.
Read More
Cancer

Suzhou Genhouse Bio discloses WRN inhibitors for cancer

July 22, 2025
Work at Suzhou Genhouse Bio Co. Ltd. has led to the identification of Werner syndrome ATP-dependent helicase (WRN; RECQ3; RECQL2) inhibitors reported to be useful for the treatment of cancer.
Read More
Cancer

New WRN inhibitors disclosed in Breakpoint Therapeutics patent

June 16, 2025
Breakpoint Therapeutics GmbH has divulged Werner syndrome ATP-dependent helicase (WRN; RECQ3; RECQL2) inhibitors reported to be useful for the treatment of cancer.
Read More
Cancer cells under magnifying glass
Cancer

SNV-5686 selectively degrades WRN in MSI-H cancer models

May 23, 2025
No Comments
Tumors with high levels of microsatellite instability (MSI-H), such as some subsets of colorectal, endometrial and gastric cancers, are associated with a hypermutated phenotype and a specific dependency on the WRN gene. Pharmacologic inhibition of WRN has been shown to selectively impair the viability of MSI-H cancer cells, effectively blocking tumor growth while sparing microsatellite-stable (MSS) cells.
Read More
Previous 1 2 3 4 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Nov. 4, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Nov. 4, 2025.
  • FGF5 gene involved in excessive hair growth

    BioWorld Science
    Hirsutism is the excessive hair growth in women in male-typical areas, usually associated with androgen excess and other conditions such as polycystic ovary...
  • Illustration of RNA strands in red and white

    LINC01354 is a prognostic marker in esophageal cancer

    BioWorld Science
    Esophageal cancer is among the most lethal cancers with a high mortality rate worldwide. Chinese researchers have explored the potential link between long...
  • Precision targeted therapy concept illustrated by dart hitting bullseye of target

    At AACR-NCI-EORTC 2025, new strategies reshape the field

    BioWorld Science
    During the first poster session of the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held in Boston, several...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe